



BerGenBio ASA: Share capital increase

Bergen, Norway, 30 April 2021 - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 23 April 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of options pursuant to the Company's share option program. A total of 66,173 options were exercised and 66,173 new shares were issued at an average subscription price of NOK 17.46 per share.

The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 8,788,775.50 divided into 87,887,755 shares, each with a nominal value of NOK 0.10.

-End-

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.